Back to Journals » Biologics: Targets and Therapy » Volume 12 » default

Biologics: Targets and Therapy

Archive: Volume 12, 2018

Focus on biosimilar etanercept – bioequivalence and interchangeability

Cantini F, Benucci M

Biologics: Targets and Therapy 2018, 12:87-95

Published Date: 30 August 2018

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y

Biologics: Targets and Therapy 2018, 12:75-86

Published Date: 20 August 2018

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation

Hakimian S, Popov Y, Rupawala AH, Salomon-Escoto K, Hatch S, Pellish R

Biologics: Targets and Therapy 2018, 12:61-67

Published Date: 27 February 2018

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases

Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F

Biologics: Targets and Therapy 2018, 12:37-41

Published Date: 31 January 2018

Analytical characterization of recombinant hCG and comparative studies with reference product

Thennati R, Singh SK, Nage N, Patel Y, Bose SK, Burade V, Ranbhor RS

Biologics: Targets and Therapy 2018, 12:23-35

Published Date: 30 January 2018

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

Chen YH, Carvalho HMS, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS

Biologics: Targets and Therapy 2018, 12:1-9

Published Date: 12 January 2018